# A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

> **NCT03061201** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 13 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** SB-525 (PF-07055480)

## Key facts

- **NCT ID:** NCT03061201
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-21
- **Primary completion:** 2024-07-16
- **Final completion:** 2024-07-16
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061201, "A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03061201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*